MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202547097773 A) filed by Sartar Therapeutics Oy, Helsinki, on Oct. 10, for 'a pharmaceutical composition for subcutaneous injection of anagrelide.'
Inventor(s) include Van Den Heuvel, Dennie; Ivanitskiy, Katja; and Maksimow, Mikael.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The present invention is directed to a pharmaceutical composition for subcutaneous injection comprising anagrelide, 3-hydroxy anagrelide or a pharmaceutically acceptable salt thereof including the hydrochloride salt thereof in a solvent comprising a medium-chain triglyceride (MCT) oil and optionally ethanol. The present invention is also directed to methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer or a myoeloproliferative disorder utilizing the pharmaceutical compositions and dosage forms provided herein."
The patent application was internationally filed on Mar. 15, 2024, under International application No.PCT/FI2024/050119.
Disclaimer: Curated by HT Syndication.
